Insulet (NASDAQ:PODD) Price Target Cut to $255.00 by Analysts at Wells Fargo & Company

Insulet (NASDAQ:PODD) had its price target lowered by Wells Fargo & Company from $360.00 to $255.00 in a note issued to investors on Wednesday,MarketScreener reports. Wells Fargo & Company‘s price target suggests a potential upside of 61.93% from the stock’s current price.

PODD has been the topic of a number of other reports. Stifel Nicolaus lowered their target price on shares of Insulet from $350.00 to $250.00 in a report on Thursday. Canaccord Genuity Group decreased their price objective on shares of Insulet from $435.00 to $249.00 in a research report on Thursday. BTIG Research lowered their price objective on shares of Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group cut their target price on shares of Insulet from $326.00 to $277.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Finally, TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a report on Monday, January 26th. Eighteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $263.91.

Insulet Stock Up 4.1%

NASDAQ PODD traded up $6.20 during trading hours on Wednesday, hitting $157.48. 81,593 shares of the company traded hands, compared to its average volume of 1,069,567. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The business’s 50-day moving average is $212.92 and its 200-day moving average is $264.96. The stock has a market capitalization of $10.91 billion, a price-to-earnings ratio of 44.72, a P/E/G ratio of 0.99 and a beta of 1.20. Insulet has a twelve month low of $148.30 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. The business’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet will post 6.27 earnings per share for the current year.

Insider Activity

In related news, Director Michael R. Minogue bought 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.36% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently bought and sold shares of PODD. Swiss National Bank boosted its holdings in shares of Insulet by 7.1% during the first quarter. Swiss National Bank now owns 206,500 shares of the medical instruments supplier’s stock worth $43,332,000 after acquiring an additional 13,600 shares during the period. Angeles Wealth Management LLC increased its stake in shares of Insulet by 5.3% during the first quarter. Angeles Wealth Management LLC now owns 2,725 shares of the medical instruments supplier’s stock worth $572,000 after purchasing an additional 136 shares during the period. C WorldWide Group Holding A S lifted its holdings in Insulet by 17.7% during the 1st quarter. C WorldWide Group Holding A S now owns 99,908 shares of the medical instruments supplier’s stock worth $20,965,000 after purchasing an additional 15,000 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. lifted its holdings in Insulet by 38.9% during the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 2,398 shares of the medical instruments supplier’s stock worth $503,000 after purchasing an additional 671 shares during the last quarter. Finally, Bessemer Group Inc. grew its holdings in Insulet by 12.3% in the 1st quarter. Bessemer Group Inc. now owns 4,024 shares of the medical instruments supplier’s stock valued at $845,000 after buying an additional 442 shares in the last quarter.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.42 vs. ~$1.19 consensus and revenue $761.7M (+33.9% Y/Y), driven by strong Omnipod demand. This confirms solid top-line momentum. Insulet Reports First Quarter 2026 Results
• Positive Sentiment: Company raised its annual revenue growth outlook after the quarter, citing sustained demand for its tubeless insulin pumps — a supportive signal for medium-term sales trajectory. Insulet lifts annual revenue forecast after quarterly beat
• Neutral Sentiment: Earnings call commentary was broadly upbeat (Omnipod growth emphasized) and management provided slide materials/transcripts for investors to parse execution details. These materials clarify drivers but don’t change the headline beat. Q1 2026 Earnings Call Transcript
• Negative Sentiment: FY 2026 EPS guidance appears below some Street estimates (company set FY EPS around ~6.21 vs. ~6.33 consensus cited by analysts), which likely disappointed investors despite the revenue upgrade. Earnings and guidance details
• Negative Sentiment: BTIG cut its price target from $320 to $260 (still a Buy rating); the PT reduction signals some analyst re?valuation and may have amplified selling pressure. BTIG price target cut

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.